Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company is headquartered in Cincinnati, Ohio and currently employs 5 full-time employees. The company went IPO on 2022-02-18. The firm owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Follow-Up Questions
ONCO 주식의 가격 성능은 어떻습니까?
ONCO의 현재 가격은 $3이며, 전 거래일에 decreased 0% 하였습니다.
Onconetix Inc의 주요 사업 주제나 업종은 무엇입니까?
Onconetix Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
